Search research articles
Contact Us
Filters
Showing results (1061-1070 of 1,467) with videos related to
Page
of 147
Sort By:
Annals of the Rheumatic Diseases
|
September 15, 2001
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine
D L Scott, J S Smolen, J R Kalden, et al.
Postgraduate Medicine
|
November 19, 2010
Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports
David K Miller, Abdalla Bowirrat, Matthew Manka, et al.
Annals of the Rheumatic Diseases
|
October 19, 2022
Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis
Irina Gessl, Claudia A Hana, Thomas Deimel, et al.
Annals of the Rheumatic Diseases
|
February 7, 2009
Interleukin-1 is essential for systemic inflammatory bone loss
K Polzer, L Joosten, J Gasser, et al.
Disease Models & Mechanisms
|
September 18, 2016
Cartilage damage and bone erosion are more prominent determinants of functional impairment in longstanding experimental arthritis than synovial inflammation
Silvia Hayer, Gregor Bauer, Martin Willburger, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
January 4, 2024
Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective
Jorge Mestre-Ferrandiz, Marcin Czech, Josef S Smolen, et al.
Arthritis Research & Therapy
|
September 11, 2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Josef S Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 5, 2002
Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis
Ruth Fritsch, Daniela Eselböck, Karl Skriner, et al.
Modern Rheumatology
|
February 21, 2019
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Masayoshi Harigai, Tsutomu Takeuchi, Josef S Smolen, et al.
Genes & Development
|
August 21, 2007
A Rap GTPase interactor, RADIL, mediates migration of neural crest precursors
Gromoslaw A Smolen, Benjamin J Schott, Rodney A Stewart, et al.
Page
of 147
Search research articles
Search
Showing results (1061-1070 of 1,467) with videos related to
Sort By:
Page
of 147
Annals of the Rheumatic Diseases
|
September 15, 2001
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine
D L Scott, J S Smolen, J R Kalden, et al.
Postgraduate Medicine
|
November 19, 2010
Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports
David K Miller, Abdalla Bowirrat, Matthew Manka, et al.
Annals of the Rheumatic Diseases
|
October 19, 2022
Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis
Irina Gessl, Claudia A Hana, Thomas Deimel, et al.
Annals of the Rheumatic Diseases
|
February 7, 2009
Interleukin-1 is essential for systemic inflammatory bone loss
K Polzer, L Joosten, J Gasser, et al.
Disease Models & Mechanisms
|
September 18, 2016
Cartilage damage and bone erosion are more prominent determinants of functional impairment in longstanding experimental arthritis than synovial inflammation
Silvia Hayer, Gregor Bauer, Martin Willburger, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
January 4, 2024
Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective
Jorge Mestre-Ferrandiz, Marcin Czech, Josef S Smolen, et al.
Arthritis Research & Therapy
|
September 11, 2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Josef S Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 5, 2002
Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis
Ruth Fritsch, Daniela Eselböck, Karl Skriner, et al.
Modern Rheumatology
|
February 21, 2019
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Masayoshi Harigai, Tsutomu Takeuchi, Josef S Smolen, et al.
Genes & Development
|
August 21, 2007
A Rap GTPase interactor, RADIL, mediates migration of neural crest precursors
Gromoslaw A Smolen, Benjamin J Schott, Rodney A Stewart, et al.
Page
of 147